Literature DB >> 26862920

False-Negative Cases on Confocal Microscopy Examination: A Retrospective Evaluation and Critical Reappraisal.

Valeria Coco1, Francesca Farnetani, Anna Maria Cesinaro, Silvana Ciardo, Giuseppe Argenziano, Ketty Peris, Giovanni Pellacani, Caterina Longo.   

Abstract

BACKGROUND: Confocal microscopy is a second-level examination for dermoscopically equivocal melanocytic lesions. However, the number of false-negative cases on confocal microscopy and the scenarios in which confocal microscopy may fail have not been fully elucidated.
OBJECTIVE: To calculate the percentage of false-negative melanomas upon reflectance confocal microscopy examination in a large series of cases.
METHODS: A retrospective analysis on 201 melanomas, evaluated for dermoscopic/confocal criteria of melanoma, was carried out.
RESULTS: Twenty-three melanomas out of 201 cases (11.4%) revealed a low 7-point checklist score. On confocal examination, 22 out of 23 lesions have been diagnosed correctly as melanomas. Only 1 lesion did not display melanoma features, neither upon dermoscopy nor upon confocal microscopy examination. Seven lesions out of 201 cases (3.5%) were judged as negative on confocal examination, even if 6 of them were diagnosed as melanomas by clinical and/or dermoscopic evaluation. After histopathological revision, these cases were grouped into 5 categories: (1) amelanotic melanoma (n = 1), (2) hyperkeratotic melanomas (n = 2), (3) lentiginous melanomas (n = 2), (4) melanoma with small pagetoid cells (n = 1), (5) spitzoid melanoma (n = 1).
CONCLUSION: Confocal and dermoscopic examination, along with patient-related information and clinical history, can lead to an optimal patient management.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 26862920     DOI: 10.1159/000443637

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  1 in total

Review 1.  Discriminating Nevi from Melanomas: Clues and Pitfalls.

Authors:  Cristina Carrera; Ashfaq A Marghoob
Journal:  Dermatol Clin       Date:  2016-10       Impact factor: 3.478

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.